publication venue for
- COPD and Metabolic Syndrome: Unanswered Questions and Opportunities for Innovation.. 11. 2024
- Design of the SPIROMICS Study of Early COPD Progression: SOURCE Study. 2024
- Multimorbidities in COPD are Associated With Increased Exacerbations and Health Care Resource Utilization in Real-World Patients from a U.S. Database. 2024
- Any Decrease in Lung Function is Associated With Worse Clinical Outcomes: Post Hoc Analysis of the IMPACT Interventional Trial. 2023
- Lung Structure and Risk of Sleep Apnea in SPIROMICS. 2023
- Disparities in Guideline Concordant Statin Treatment in Individuals with Chronic Obstructive Pulmonary Disease. 2023
- Changes in Lung Volumes with Spirometric Disease Progression in COPD. 2023
- Impact of Bronchiectasis on COPD Severity and Alpha-1 Antitrypsin Deficiency as a Risk Factor in Individuals with a Heavy Smoking History. 2023
- Impact of Marijuana Smoking on COPD Progression in a Cohort of Middle-Aged and Older Persons. 2023
- Mortality Risk and Serious Cardiopulmonary Events in Moderate-to-Severe COPD: Post Hoc Analysis of the IMPACT Trial.. 10. 2023
- Impact of the Coronavirus Disease 2019 Pandemic on Physical and Mental Health of Patients With COPD: Results From a Longitudinal Cohort Study Conducted in the United States (2020-2021). 2022
- Chronic Obstructive Pulmonary Disease and Lung Cancer: A Review for Clinicians.. 9. 2022
- Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Instrument.. 9. 2022
- Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort.. 9. 2022
- Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT Trial.. 9. 2022
- Polycythemia is Associated with Lower Incidence of Severe COPD Exacerbations in the SPIROMICS Study.. 8. 2021
- Does Evaluation and Management of COPD Follow Therapeutic Strategy Recommendations?. 8. 2021
- InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions.. 8. 2021
- Protocol Summary of the COPD Assessment in Primary Care To Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE) Validation in Primary Care Study.. 8. 2021
- COPDGene® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease.. 6. 2019
- Mortality and Exacerbations by Global Initiative for Chronic Obstructive Lung Disease Groups ABCD: 2011 Versus 2017 in the COPDGene® Cohort.. 6. 2019
- Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study.. 4. 2016
- Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus.. 4. 2016
- The Human Microbiome in the Lung: Are Infections Contributing to Lung Health and Disease?. 3. 2016
- Insight into Best Variables for COPD Case Identification: A Random Forests Analysis.. 3. 2016
- Identifying Patients with Undiagnosed COPD in Primary Care Settings: Insight from Screening Tools and Epidemiologic Studies.. 2. 2015